Nanosize Non-Viral Gene Therapy Reverses Senescence Reprograming Driven by PBRM1 Deficiency to Suppress iCCA...

Area of Science:

• Oncology
• Molecular Biology
• Gene Regulation

Background:

• Polybromo-1 (PBRM1) is a key transcriptional regulator implicated in various cancers.
• Its specific function and regulatory mechanisms in intrahepatic cholangiocarcinoma (iCCA) remain largely undefined.
• Understanding PBRM1's role is crucial for developing novel iCCA therapeutic strategies.

Purpose of the Study:

• To elucidate the role of PBRM1 in iCCA pathogenesis and progression.
• To investigate the molecular mechanisms underlying PBRM1's regulation of iCCA.
• To develop and evaluate a nanomedicine-based gene therapy for iCCA targeting PBRM1 expression.

Main Methods:

• Analysis of PBRM1 expression levels in iCCA tissues and correlation with clinicopathological features.
• In vivo studies using a gene therapy nanomedicine to modulate PBRM1 expression in iCCA models.
• Investigation of the ERK1/2 signaling pathway, p16, p53/p21 expression, and cellular senescence.
• Pharmacological inhibition of ERK1/2 signaling using U0126.

Main Results:

• PBRM1 expression is significantly downregulated in iCCA, correlating with aggressive disease and poor prognosis.
• PBRM1 downregulation activates the ERK1/2 pathway, reduces senescence markers (p16, p53/p21), and promotes iCCA progression.
• Nanomedicine-mediated PBRM1 upregulation effectively inhibited iCCA tumor growth in vivo.
• Inhibition of ERK1/2 signaling with U0126 reversed iCCA progression by modulating the PBRM1-ERK1/2-cellular senescence axis.

Conclusions:

• PBRM1 acts as a tumor suppressor in iCCA, and its reduced expression is a critical driver of disease progression.
• The PBRM1-ERK1/2-cellular senescence pathway represents a novel therapeutic target for iCCA.
• Gene therapy nanomedicine targeting PBRM1 and ERK1/2 inhibition show significant therapeutic potential for iCCA treatment.